In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endocrine disruptor screening tests

This article was originally published in The Rose Sheet

Executive Summary

National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods makes available final report on Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors, according to June 3 Federal Register 1notice. Report features ICCVAM's recommendations on minimum procedural standards for standardization and validation of in vitro estrogen and androgen receptor binding and transcriptional activation assays, NICEATM says. Document also includes list of substances, including three phthalates, proposed for validation of the screening methods. In October, NICEATM solicited comments on an expert panel report on the status of in vitro endocrine disruptor methods (2"The Rose Sheet" Oct. 28, 2002, In Brief)...

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts